| Code | CSB-RA822274MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of enfortumab vedotin, targeting NECTIN4 (nectin cell adhesion molecule 4), also known as PVRL4. NECTIN4 is a calcium-independent immunoglobulin-like transmembrane adhesion protein that mediates cell-cell interactions and regulates cellular proliferation, migration, and epithelial-to-mesenchymal transition. Unlike other nectin family members expressed broadly in normal tissues, NECTIN4 exhibits minimal expression in healthy adult organs but is significantly overexpressed in multiple malignancies, including urothelial, breast, lung, pancreatic, and ovarian cancers. NECTIN4 promotes tumor progression through activation of PI3K/Akt and Rac1 signaling pathways, contributing to angiogenesis, metastasis, and poor prognosis. Enfortumab vedotin is an FDA-approved antibody-drug conjugate consisting of a fully human anti-NECTIN4 monoclonal antibody linked to the microtubule inhibitor MMAE via a protease-cleavable linker. This biosimilar provides the antibody component alone, enabling researchers to investigate NECTIN4 biology, cell adhesion mechanisms, and tumor-associated signaling pathways independent of cytotoxic payload effects. It supports studies exploring NECTIN4 as a therapeutic target and facilitates development of novel NECTIN4-directed strategies in oncology research.
There are currently no reviews for this product.